TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The infant will be assessed sequentially by criteria A, B and C, as described by the TOBY trial and listed below, to be eligible for hypothermia treatment.~   A. Infants ≥ 36 completed weeks of gestation admitted to the NICU with at least one of the following:~  * Apgar score of ≤ 5 at 10 minutes after birth~  * Continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes after birth~  * Acidosis within 60 minutes of birth (defined as any occurrence of umbilical cord, arterial or capillary pH \< 7.00)~  * Base Deficit ≥ 16 mmol/L in umbilical cord or any blood sample (arterial, venous or capillary) within 60 minutes of birth~   B. Moderate to severe encephalopathy, consisting of altered state of consciousness (lethargy, stupor or coma) AND at least one of the following:~  * hypotonia~  * abnormal reflexes including oculomotor or pupillary abnormalities~  * absent or weak suck~  * clinical seizures~   C. At least 30 minutes duration of aEEG recording that shows abnormal background aEEG activity or seizures. There must be one of the following:~  * normal background with some seizure activity~  * moderately abnormal activity~  * suppressed activity~  * continuous seizure activity~2. Invasive arterial blood pressure measurement: umbilical arterial catheter or peripheral arterial catheter to measure invasively the arterial blood pressure.~3. During hypothermia treatment low blood pressure was detected and treated with the following:~   * fluid therapy: 10-20 ml/kg isotonic NaCl if hypotension is still present~  * inotropic therapy: dopamine in parallel with study intervention~4. A written informed consent has been obtained from a parent of each infant after explanation of the study.~Exclusion Criteria:~1. Signed informed consent is unavailable.~2. Infants who are expected to be \> 6 hours of age (not suitable for cooling).~3. Congenital abnormalities, cardiac anomalies, meconium aspiration syndrome.~4. Low blood pressure coincides with high heart rate (\>120/min) in cooled infants, suggesting hypovolaemia.~5. Haematocrit level \< 35%.~6. Need for combined, ≥2 types of inotropic therapy.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Hydrocortisone (Type: ACTIVE_COMPARATOR): Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
- Placebo (Type: PLACEBO_COMPARATOR): Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18\~75,both gender.~* Patients with upper gastrointestinal symptoms and with documented H.pylori infection.~* Patients are willing to receive eradication treatment.~* Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.~Exclusion Criteria:~* Patients are excluded if they have previously used antibiotics to eradicate adequately recorded infection with H. pylori.~* Contraindications to study drugs.~* Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.~* Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the \[13C\] urea breath test),antibiotics or bismuth complexes (more than 3 times /1 month before screening).~* Patients were diagnosed with gastroduodenal ulcer and MALTlymphoma.~* Pregnant or lactating women.~* Underwent upper gastrointestinal Surgery.~* Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of dysphagia.~* Evidence of bleeding or iron efficiency anemia.- Page 3 of 4 \[DRAFT\] -~* A history of malignancy.~* Drug or alcohol abuse history in the past 1 year.~* Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).~* Patients who has psychological problem or poor compliance.~* Enrolled in other clinical trials in the past 3 months.~* Refuse to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bismuth potassium citrate containing quadruple therapy (Type: ACTIVE_COMPARATOR): Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
- Colloidal pectin bismuth capsules containing quadruple therapy (Type: ACTIVE_COMPARATOR): Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
- Colloidal pectin bismuth particles A quadruple therapy (Type: ACTIVE_COMPARATOR): Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
- Colloidal pectin bismuth particles B quadruple therapy (Type: ACTIVE_COMPARATOR): Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms~* clinically stable as determined by the investigator (pulmonologist)~Exclusion Criteria:~* intolerant to hypertonic saline.~* FEV1%p \<40% of predicted~* nursing mother~* positive urine pregnancy test~* unwilling to stop hypertonic saline therapy for 72 hours prior to each test day~* cigarette smoker (regular smoking within 6 months of study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- isotonic saline then hypertonic saline (Type: ACTIVE_COMPARATOR): Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.
- hypertonic saline then isotonic saline (Type: ACTIVE_COMPARATOR): Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 y.o.~* Claudication in Rutherford Class 1-5,~* Lesion in the femoropopliteal artery defined as \>50% and \< 99% diameter stenosis with length of up to 10 cm in vessel diameter of 3-7 mm~* Chronic total occlusions of length less than 100 mm~* Ability to cross the lesions with a guidewire.~Exclusion Criteria:~* Critical acute or chronic limb ischemia~* Acute coronary syndrome~* Chronic kidney disease stage III-V~* Restenotic lesion~* Femoropopliteal graft~* Known allergy to clopidogrel or aspirin~* History of stroke within past 6 months~* Age \> 80 y.o.~* Life expectancy \< 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Plain Balloon Angioplasty (Type: ACTIVE_COMPARATOR): Plain Balloon Angioplasty
- microcrystalline Paclitaxel Coated Balloon (PAK) (Type: EXPERIMENTAL): plain balloon angioplasty followed by mcPCB dilation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Denosumab in Erosion Healing in RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* DAS28 ≤5.1~* without severe deformity in MCP joints which would influence the longitudinal assessment of HR-pQCT~Exclusion Criteria:~* RA functional status class IV (limited in ability to perform usual self-care, vocational, and avocational activities)~* treatment with any biologic DMARDs for RA treatment within 8 weeks before randomisation~* pregnancy or premenopausal women planning pregnancy~* previous use of denosumab, zoledronic acid or teriparatide~* Hyperparathyroidism~* contraindications to denosumab~* Bisphosphonate, biologic DMARDs and the use of oral glucocorticoid \>10 mg/day (prednisolone equivalent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: ACTIVE_COMPARATOR): Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria~2. Not in MDA at the time of screening~3. Has 3 or more tender and 3 or more swollen joints~4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks~Exclusion Criteria:~1. Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or its excipients~2. History of methotrexate intolerance/toxicity~3. Medical conditions(s) precluding methotrexate dose increase above 15 mg~4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of action biologic DMARD (bDMARD) or any systemic biologic agent in general

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: MTX Escalated Dose (Type: ACTIVE_COMPARATOR): Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
- Part 1: ADA + MTX (Type: EXPERIMENTAL): Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
- Part 2: MTX Escalated Dose (Type: ACTIVE_COMPARATOR): Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
- Part 2: ADA + MTX Escalated Dose (Type: ACTIVE_COMPARATOR): Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
- Part 2: ADA (Type: EXPERIMENTAL): Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
- Part 2: ADA ew + MTX (Type: EXPERIMENTAL): Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women who have been newly diagnosed with post-menopausal osteoporosis, requiring treatment;~* naive to bisphosphonate treatment,or had bisphosphonate treatment for a maximum of 3 months, at least 5 years before screening.~Exclusion Criteria:~* patients on hormone replacement therapy (HRT) within the last 3 months;~* patients on other osteoporosis medication within the last 3 months;~* sCTX below lower limit, or above 3 times the upper limit, of normal premenopausal level;~* hypersensitivity to any component of ibandronate;~* contraindication for calcium or vitamin D therapy;~* history of major gastrointestinal upset;~* malignant disease diagnosed within the previous 10 years (except resected basal cell cancer).

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance After Initiation of Nutrition TrAINing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \>= 30 kg/m2~* Desire to lose weight~* Agrees to attend regular visits per study protocol~* Has a provider at the Durham Veterans Affairs Medical Center~Exclusion Criteria:~* Age \>= 75 years old,~* Most recent serum creatinine \>2.0 mg/dL in men, \>1.7 mg/dL in women),~* Liver disease (cirrhosis, jaundice, or other stigmata of advanced liver disease),~* Type 1 diabetes,~* Hemoglobin A1c \>= 12% in past 6 months~* unstable angina or coronary ischemia workup in past 3 months~* Female: pregnancy, breastfeeding, or lack of birth control if premenopausal~* Transplant recipient~* Pacemaker or defibrillator (bioelectric impedance assessment might interfere with these)~* Average systolic blood pressure in the past year \>= 160 mmHg AND most recent BP \>=160 mmHg~* Dementia, severe psychiatric illness (e.g., major depression), alcohol problem, or illicit substance abuse~* Weight loss of at least 10 lb in previous 3 months~* Enrollment in a weight loss program~* Unable to stand for study measurements~* history of weight loss surgery~* cancer not in remission~* current use of appetite suppressants or weight loss medication~* lack of reliable transportation or telephone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Maintenance intervention (Type: EXPERIMENTAL): Participants receive a theoretically-informed maintenance intervention for 42 weeks, followed by 14 weeks of no intervention contact to examine sustainability. The maintenance intervention involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
- Usual care (Type: NO_INTERVENTION): Participants receive usual care for 56 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18-85 years who have given written informed consent.~* Subjects with a body mass index within 15-35 kg/m2 (Quetelet's index).~Exclusion Criteria:~* Subjects with history or evidence of keloid scarring.~* Subjects with tattoos or previous scars within 3cm of the area to be incised.~* Subjects who had surgery in the area to be incised within one year of the first dosing day.~* Subjects with history of a bleeding disorder or who were receiving anti-coagulant or anti-platelet therapy.~* Subjects with evidence of any past or present clinically significant disease that may affect the endpoints of the trial.~* Subjects with a clinically significant skin disorder that was chronic or currently active.~* Subjects with any clinically significant medical condition or history that would impair wound healing.~* Subjects with history of hypersensitivity to any of the drugs or dressings used in this trial.~* Subjects taking, or who have taken, any investigational product or who had participated in a clinical trial in the three months prior to first trial dose administration.~* Subjects taking regular, continuous, oral corticosteroid therapy.~* Subjects undergoing investigations or changes in management for an existing medical condition.~* Subjects with a history of drug abuse, or with a positive drugs of abuse test for cocaine, amphetamines, methamphetamines, opiates or benzodiazepines during the screening period.~* Subjects who, in the opinion of the investigator, were unlikely to complete the trial for whatever reason.~* Subjects who had any clinically significant neurological impairment or disease.~* Subjects with any active infection.~* Subjects who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic RLS~Exclusion Criteria:~* History of sleep disturbances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weight Management in Rural Communities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index 25 to 45 kg/m2~* Clearance from primary care physician~Exclusion Criteria:~* Unable to participate in moderate intensity physical activity~* Participation in weight loss or physical activity program in previous 6 months~* Greater than 3, 30-min bouts of planned exercise/week~* Not weight stable (+/-4.6 kg) for 3 months prior to intake~* Unwilling to be randomized to 1 of the 3 study groups~* Report being pregnant during the previous 6 months or planned pregnancy in the following 18 months~* Serious medical risk such as cancer, recent cardiac event~* Current use of antipsychotics or untreated depression~* Adherence to specialized diet regimens (food allergy, vegetarian, macrobiotic)~* Binge eating disorder~* Planning to movie to a location and no longer having access to rural clinic site

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group Phone Conference Call (Type: EXPERIMENTAL): Delivery: Group Phone Diet: PCMs
- Individual Phone Call (Type: EXPERIMENTAL): Delivery: Individual Phone Call Diet: PCMs
- Enhanced Usual Care (Type: ACTIVE_COMPARATOR): Delivery: Face-to-Face Diet: Conventional Diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete